DK3055429T3 - Fremgangsmåde til prognose og behandling af metastaserende cancer i knoglerne, som hidrører fra brystcancer - Google Patents

Fremgangsmåde til prognose og behandling af metastaserende cancer i knoglerne, som hidrører fra brystcancer Download PDF

Info

Publication number
DK3055429T3
DK3055429T3 DK14824529.3T DK14824529T DK3055429T3 DK 3055429 T3 DK3055429 T3 DK 3055429T3 DK 14824529 T DK14824529 T DK 14824529T DK 3055429 T3 DK3055429 T3 DK 3055429T3
Authority
DK
Denmark
Prior art keywords
maf
inhibitor
breast cancer
gene
amplification
Prior art date
Application number
DK14824529.3T
Other languages
English (en)
Inventor
Roger Gomis
Evarist Planet
Milica Pavlovic
Anna Arnal
Maria Tarragona
Original Assignee
Fundacio Inst De Recerca Biomedica Irb Barcelona
Inst Catalana Recerca Estudis Avancats
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacio Inst De Recerca Biomedica Irb Barcelona, Inst Catalana Recerca Estudis Avancats filed Critical Fundacio Inst De Recerca Biomedica Irb Barcelona
Application granted granted Critical
Publication of DK3055429T3 publication Critical patent/DK3055429T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (12)

1. In wfro-fremgangsmåde til forudsigelse af risikoen for knoglemetastase af en HER2+ brystcancer og/eller det kliniske resultat af en HER2+ brystcancer hos et individ, der har denne cancer, hvilken fremgangsmåde omfatter i) at bestemme amplifikationen eller kopiantallet af MAF-genet i en HER2+ brystcancerprøve fra individet og ii) at sammenligne amplifikationen eller kopiantallet opnået i trin i) med en referenceværdi, hvor øget kopiantal eller grad af amplifikation af genet med hensyn til referenceværdien indikerer øget risiko for at udvikle knoglemetastaser og/eller et dårligt klinisk resultat.
2. In vitro-fremgangsmåde til udformning af en individuelt tilpasset terapi til et individ, der har HER2+ brystcancer, hvilken fremgangsmåde omfatter: i) at bestemme MAF-genamplifikationen eller kopiantallet i en FIER2+ brystcancerprøve fra individet og ii) at sammenligne amplifikationen eller kopiantallet opnået i trin i) med en referenceværdi, hvor, hvis kopiantallet eller graden af amplifikation øges i forhold til referenceværdien, så er individet modtagelig for en terapi, der har til formål at forebygge eller behandle knoglemetastase, og/eller en terapi, der har til formål at undgå og/eller forebygge knoglenedbrydning, hvor, hvis kopiantallet eller graden af amplifikation ikke øges i forhold til en referenceværdi, så er individet ikke modtagelig for en terapi, der har til formål at forebygge og/eller behandle knoglemetastase og/eller en terapi, der har til formål at undgå og/eller behandle knoglenedbrydning.
3. In wfro-fremgangsmåde til forudsigelse af risikoen for knoglemetastase ifølge krav 1, hvor et kopiantal eller en grad af amplifikation af genet over den gennemsnitlige værdi plus en standardafvigelse indikereren øget risiko for tidlig knoglemetastase.
4. Fremgangsmåde ifølge krav 2, hvor terapien til undgåelse eller forebyggelse af knoglenedbrydning er udvalgt fra gruppen bestående af et biphosphonat, en RANKL-inhibitor, en PTH-inhibitor, en PTHLH-inhibitor, en PRG-analog, stron-tiumranelat, en DKK-1 -inhibitor, en dobbelt-inhibitor af MET og VEGFR2, en østrogenreceptormodulator, calcitonin, radium-223 og en cathepsin K-inhibi-tor, og/eller terapien til forebyggelse eller behandling af metastase er udvalgt fra gruppen bestående af: et c-MAF-hæmmende middel, systemiske behandlinger, herunder, men ikke begrænset til: kemoterapi, hormonbehandling, im-minterapi, stråleterapi, kirurgi, en mTor-inhibitor, en Src-kinase-inhibitor, en CCR5-antagonist, en COX-2-inhibitor og alpharadin.
5. Fremgangsmåde ifølge krav 4, hvor RANKL-inhibitoren er udvalgt fra gruppen bestående af et RANKL-specifikt antistof, et RANKL-specifikt nanobody, osteoprotegerin, bisphosphonat-zoledronsyre og dobbelt-inhibitoren cabozantinib af MET og VEGFR2.
6. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 5, hvor det at bestemme MAF-amplifikationen eller kopiantallet omfatter at kvantificering af kopiantallet eller amplifikation af protein, der kodes af genet eller af en variant deraf, hvor kopiantallet eller amplifikationen af protein kvantificeres ved hjælp af western blot, ELISA, FISH, immunhistokemi eller protein-array eller kvantificering af messenger-RNA'en (mRNA) af genet eller et fragment af mRNA'en, den komplementære DNA (cDNA) af genet eller et fragment af cDNA'en.
7. In wtro-fremgangsmåde til forudsigelse af risikoen for knoglemetastase og/eller forudsigelse af det kliniske resultat af en HER2+ brystcancer ifølge krav 1, omfattende at bestemme, om MAF-genet er amplificeret i HER2+ brystcancerprøven fra individet i forhold til et reference-gen kopiantal, hvor en amplifikation af MAF-genet i forhold til reference-genkopiantallet indikerer en øget risiko for at udvikle knoglemetastase og/eller et dårligt klinisk resultat.
8. Middel, der er i stand til at forhindre eller forebygge knoglenedbrydning, til anvendelse til forebyggelse, inhibering eller behandling af knoglemetastase fra HER2+ brystcancer eller forhindre eller forebygge knoglenedbrydning ved HER2+ brystcancer hos et individ, der er blevet identificeret som havende en amplifikation af MAF-genet eller et øget kopiantal i forhold til en referenceværdi, hvor midlet, der er i stand til at forhindre eller forebygge knoglenedbryd ning, er udvalgt fra gruppen bestående af et bisphosphonat, en RANKL-inhibi-tor, en PTH- eller PTHLH-inhibitor, herunder blokerende antistoffer eller re-kombinante former deraf, en PRG-analog, strontiumranelat, en DKK-1-inhibitor, en dobbelt-inhibitor af MET og VEGFR2, en østrogenreceptormodulator, calcitonin, en cathepsin K-inhibitorog alpharadin.
9. Middel, der er i stand til at forhindre eller forebygge knoglenedbrydning, til anvendelse til behandling, inhibering eller forebyggelse af knoglemetastase fra HER2+ brystcancer eller knoglenedbrydning ifølge krav 8, hvor midlet er udvalgt fra gruppen bestående af et bisphosphonat, en RANKL-inhibitor, en PTH-inhibitor en PTHLH-inhibitor eller en PRG-analog, strontiumranelat, en DKK- 1-inhibitor, en dobbelt-inhibitor af MET og VEGFR2, en østrogenreceptormodulator, calcitonin, radium-223 og en cathepsin K-inhibitor.
10. Middel, der er i stand til at forhindre eller forebygge knoglenedbrydning til anvendelse til behandling, inhibering eller forebyggelse af knoglemetastase fra HER2+ brystcancer eller knoglenedbrydning ifølge krav 9, hvor RANKL-inhibi-toren er udvalgt fra gruppen af et RANKL-specifikt antistof, et RANKL-specifikt nanobody, osteoprotegerin, bisphosphonat-zoledronsyre og dobbelt-inhibito-ren cabozantinib af MET og VEGFR2.
11. In vitro-fremgangsmåde til typebestemmelse af en prøve fra et individ, der lider af HER2+ brystcancer, hvilken fremgangsmåde omfatter: (a) at tilvejebringe en HER2+ brystcancerprøve fra individet; (b) at kvantificere amplifikationen eller kopiantallet af MAF i prøven; (c) at typebestemme prøven ved at sammenligne den kvantificerede amplifi-kation eller kopiantallet af MAF med et forudbestemt referenceniveau af MAF; hvor typebestemmelsen tilvejebringer prognostisk information i relation til risikoen for knoglemetastase hos individet.
12. Fremgangsmåde til klassificering af et individ, der har HER2+ brystcancer, i en kohorte, omfattende: a) at bestemme amplifikationen eller kopiantallet af MAF i en HER2+ brystcancerprøve fra individet; b) at sammenligne amplifikationen eller kopiantallet af MAF i prøven med et forudbestemt referenceniveau af MAF; og c) at klassificere individet i en kohorte på basis af amplifikationen eller kopiantallet af MAF i prøven.
DK14824529.3T 2013-10-09 2014-10-07 Fremgangsmåde til prognose og behandling af metastaserende cancer i knoglerne, som hidrører fra brystcancer DK3055429T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361888984P 2013-10-09 2013-10-09
PCT/IB2014/002675 WO2015052583A2 (en) 2013-10-09 2014-10-07 Method for the prognosis and treatment of cancer metastasis

Publications (1)

Publication Number Publication Date
DK3055429T3 true DK3055429T3 (da) 2019-04-23

Family

ID=52292968

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14824529.3T DK3055429T3 (da) 2013-10-09 2014-10-07 Fremgangsmåde til prognose og behandling af metastaserende cancer i knoglerne, som hidrører fra brystcancer

Country Status (13)

Country Link
US (1) US20170101683A1 (da)
EP (2) EP3055429B1 (da)
JP (1) JP6550045B2 (da)
KR (1) KR20160061424A (da)
CN (1) CN105980576B (da)
AU (1) AU2014333513B2 (da)
BR (1) BR112016007864A2 (da)
CA (1) CA2926894A1 (da)
DK (1) DK3055429T3 (da)
ES (1) ES2727904T3 (da)
MX (2) MX362041B (da)
TR (1) TR201907389T4 (da)
WO (1) WO2015052583A2 (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2626431T3 (da) 2010-10-06 2015-12-21 Fundació Inst De Recerca Biomèdica Irb Barcelona Fremgangsmåde til diagnose, prognose og behandling af brystcancermetastase
EP2650682A1 (en) 2012-04-09 2013-10-16 Fundació Privada Institut de Recerca Biomèdica Method for the prognosis and treatment of cancer metastasis
EP2859120B1 (en) 2012-06-06 2018-11-14 Fundació Institut de Recerca Biomèdica (IRB Barcelona) Method for the diagnosis and prognosis of lung cancer metastasis
US10119171B2 (en) 2012-10-12 2018-11-06 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
ES2744244T3 (es) 2012-10-12 2020-02-24 Inbiomotion Sl Método para el diagnóstico, pronóstico y tratamiento de metástasis de cáncer de próstata usando c-MAF
EP3272880B1 (en) 2013-03-15 2020-11-25 Fundació Institut de Recerca Biomèdica (IRB Barcelona) Method for the diagnosis, prognosis and treatment of metastatic cancer
CA2967224C (en) 2014-12-11 2023-08-22 Inbiomotion S.L. Binding members for human c-maf
KR20230128144A (ko) * 2016-05-25 2023-09-01 인바이오모션 에스.엘. c-MAF 상태에 기초한 유방암의 치료
CN105907886A (zh) * 2016-07-07 2016-08-31 蔡维泺 miR-124在乳腺癌骨转移疾病中的应用
CA3082728A1 (en) * 2017-11-22 2019-05-31 Inbiomotion S.L. Therapeutic treatment of breast cancer based on c-maf status
WO2019232280A1 (en) * 2018-05-30 2019-12-05 Purdue Research Foundation Targeting anabolic drugs for accelerated fracture repair
RU2766248C1 (ru) * 2021-01-11 2022-02-10 Федеральное государственное бюджетное научное учреждение "Томский национальной исследовательский медицинский центр Российской академии наук ("Томский НИМЦ") Способ прогнозирования статуса рецептора эпидермального фактора роста her2/neu в первичной опухоли у больных раком молочной железы
RU2757960C1 (ru) * 2021-01-11 2021-10-25 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр" Российской академии наук ("Томский НИМЦ") Способ прогнозирования статуса рецептора эпидермального фактора роста her2/neu в метастатических лимфатических узлах у больных раком молочной железы
CN113667748B (zh) * 2021-07-19 2023-07-25 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） circIKBKB的抑制剂及其检测试剂在乳腺癌骨转移诊断、治疗和预后试剂盒的应用
CN114512183B (zh) * 2022-01-27 2022-09-20 北京吉因加医学检验实验室有限公司 一种预测met基因扩增或多倍体的方法及装置

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3688418T2 (de) 1985-02-13 1993-08-26 Scios Nova Inc Menschlicher metallothionein ii-promotor in saeugetierexpressionssystemen.
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
AU734051B2 (en) 1996-04-05 2001-05-31 Salk Institute For Biological Studies, The Hormone-mediated methods for modulating expression of exogenous genes in mammalian systems, and products related thereto
JP4138013B2 (ja) 1996-12-23 2008-08-20 イミュネックス・コーポレーション Ｔｎｆスーパーファミリーのメンバーであるｎｆ−ｋａｐｐａ ｂの受容体アクティベーターに対するリガンド
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
US6274338B1 (en) 1998-02-24 2001-08-14 President And Fellows Of Harvard College Human c-Maf compositions and methods of use thereof
US6982475B1 (en) 1998-03-20 2006-01-03 Mcsp, Llc Hermetic wafer scale integrated circuit structure
TR200103390T2 (tr) 1999-03-15 2002-05-21 Axys Pharmaceuticals, Inc. Proteaz inhibitörleri olan yeni bileşikler ve terkipler.
TW404030B (en) 1999-04-12 2000-09-01 Siliconware Precision Industries Co Ltd Dual-chip semiconductor package device having malposition and the manufacture method thereof
US6287813B1 (en) 1999-04-23 2001-09-11 Cistronics Cell Technology Gmbh Antibiotic-based gene regulation system
JP2003525874A (ja) 2000-01-06 2003-09-02 メルク フロスト カナダ アンド カンパニー プロテアーゼ阻害剤としての新規化合物および組成物
US6750015B2 (en) 2000-06-28 2004-06-15 Kathryn B. Horwitz Progesterone receptor-regulated gene expression and methods related thereto
NZ530765A (en) 2001-06-26 2006-11-30 Amgen Fremont Inc Antibodies that bind OPGL and compositions and methods for the treatment of bone diseases
GB0121033D0 (en) 2001-08-30 2001-10-24 Novartis Ag Organic compounds
AR036375A1 (es) 2001-08-30 2004-09-01 Novartis Ag Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos
SE0201980D0 (sv) 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
AU2003903540A0 (en) 2003-07-09 2003-07-24 Atdec Pty Ltd Flat panel display wall mounting system
US20050060771A1 (en) 2003-09-11 2005-03-17 Farmer Andrew Alan siRNA encoding constructs and methods for using the same
JP4579246B2 (ja) * 2003-09-24 2010-11-10 オンコセラピー・サイエンス株式会社 乳癌を診断する方法
WO2005046731A1 (en) 2003-10-17 2005-05-26 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Interference with c-maf function in multiple myeloma
WO2005060722A2 (en) 2003-12-18 2005-07-07 President And Fellows Of Hardvard College Modulation of immune system function by modulation of polypeptide arginine methyltransferases
TW200526224A (en) 2003-12-22 2005-08-16 Alcon Inc Short form c-Maf transcription factor antagonists for treatment of glaucoma
US20080131940A1 (en) 2004-06-25 2008-06-05 Robert Chiu Target Cell-Specific Short Interfering Rna and Methods of Use Thereof
WO2006135436A2 (en) 2004-10-22 2006-12-21 University Of Florida Research Foundation, Inc. Inhibition of gene expression and therapeutic uses thereof
US8242081B2 (en) 2005-12-06 2012-08-14 Centre National De La Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
WO2008098351A1 (en) 2007-02-14 2008-08-21 University Health Network Treatment of d-cyclin mediated proliferative diseases and hemotological malignancies
EP1961825A1 (en) * 2007-02-26 2008-08-27 INSERM (Institut National de la Santé et de la Recherche Medicale) Method for predicting the occurrence of metastasis in breast cancer patients
CA2687903C (en) 2007-05-24 2016-09-13 Ablynx N.V. Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders
US20110130296A1 (en) 2008-03-14 2011-06-02 The Regents Of The University Of California Multi-gene classifiers and prognostic indicators for cancers
US8642270B2 (en) 2009-02-09 2014-02-04 Vm Institute Of Research Prognostic biomarkers to predict overall survival and metastatic disease in patients with triple negative breast cancer
EP2435071A1 (en) * 2009-05-29 2012-04-04 F. Hoffmann-La Roche AG Modulators for her2 signaling in her2 expressing patients with gastric cancer
CA2807557C (en) 2009-08-06 2019-09-17 Partha S. Ray Diagnosis of primary and metastatic basal-like breast cancer and other cancer types
DK2626431T3 (da) * 2010-10-06 2015-12-21 Fundació Inst De Recerca Biomèdica Irb Barcelona Fremgangsmåde til diagnose, prognose og behandling af brystcancermetastase
AU2012229123B2 (en) * 2011-03-15 2017-02-02 British Columbia Cancer Agency Branch Methods of treating breast cancer with anthracycline therapy
EP2650682A1 (en) * 2012-04-09 2013-10-16 Fundació Privada Institut de Recerca Biomèdica Method for the prognosis and treatment of cancer metastasis

Also Published As

Publication number Publication date
CN105980576B (zh) 2021-07-16
TR201907389T4 (tr) 2019-06-21
ES2727904T3 (es) 2019-10-21
JP2016539625A (ja) 2016-12-22
MX2016004557A (es) 2016-07-22
AU2014333513B2 (en) 2020-11-26
EP3055429A2 (en) 2016-08-17
AU2014333513A1 (en) 2016-04-28
CN105980576A (zh) 2016-09-28
WO2015052583A3 (en) 2015-07-23
BR112016007864A2 (pt) 2017-12-05
MX362041B (es) 2019-01-07
MX2019000091A (es) 2023-04-27
KR20160061424A (ko) 2016-05-31
WO2015052583A2 (en) 2015-04-16
EP3524698A1 (en) 2019-08-14
US20170101683A1 (en) 2017-04-13
JP6550045B2 (ja) 2019-07-24
CA2926894A1 (en) 2015-04-16
EP3055429B1 (en) 2019-03-27

Similar Documents

Publication Publication Date Title
DK3055429T3 (da) Fremgangsmåde til prognose og behandling af metastaserende cancer i knoglerne, som hidrører fra brystcancer
KR102442275B1 (ko) 암 전이의 예후 및 치료 방법
DK2859120T3 (da) Fremgangsmåde til diagnose af og prognose for lungecancermetastase
AU2016213773B2 (en) Method for the diagnosis, prognosis and treatment of prostate cancer metastasis using c-MAF
KR20150122731A (ko) 암 전이의 예후 및 치료 방법
KR20230128144A (ko) c-MAF 상태에 기초한 유방암의 치료
WO2014184679A2 (en) Method for the prognosis and treatment of renal cell carcinoma metastasis
AU2013328385B2 (en) Method for the diagnosis, prognosis and treatment of prostate cancer metastasis using c-MAF